• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

    7/25/24 6:36:30 AM ET
    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Industrial Specialties
    Health Care
    Movies/Entertainment
    Consumer Discretionary
    Get the next $BBLG alert in real time by email

    Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program.

    Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million.

    Indivior shares jumped 14.5% to $12.46 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.
    • BloomZ Inc. (NASDAQ:BLMZ) gained 81.2% to $4.44 in pre-market trading after dipping 43% on Wednesday. BloomZ recently priced its IPO at $4.30 per share.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) shares climbed 51.4% to $0.4576 in pre-market trading.
    • CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) gained 41.5% to $0.2988 in pre-market trading after gaining around 8% on Wednesday.
    • Viking Therapeutics, Inc. (NASDAQ:VKTX) shares gained 20.8% to $60.90 in pre-market trading after the company reported better-than-expected second-quarter EPS results.
    • Signing Day Sports, Inc. (NYSE:SGN) shares gained 15.9% to $0.2231 in pre-market trading after falling over 12% on Wednesday.
    • Stellus Capital Investment Corporation (NYSE:SCM) shares surged 15.6% to $16.41 in pre-market trading.
    • ELEVAI Labs Inc (NASDAQ:ELAB) gained 15.4% to $0.52 in pre-market trading.
    • Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares gained 7.9% to $16.60 in pre-market trading. Ipsen and Day One entered into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor.

    Losers

    • 2U, Inc. (NASDAQ:TWOU) shares fell 67.7% to $1.33 in pre-market trading. 2U announced a strategic agreement with debtholders to eliminate half of debt and infuse $110 million in new capital.
    • IF Bancorp, Inc. (NASDAQ:IROQ) shares declined 59.6% to $6.97 in pre-market trading.
    • Edwards Lifesciences Corporation (NYSE:EW) shares fell 22% to $67.85 in pre-market trading after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.
    • Selina Hospitality PLC (NASDAQ:SLNA) shares fell 19.7% to $0.0367 in pre-market trading after jumping over 75% on Wednesday.
    • Ostin Technology Group Co., Ltd. (NASDAQ:OST) shares declined 18.7% to $0.36 in pre-market trading after gaining around 19% on Wednesday.
    • MaxLinear, Inc. (NYSE:MXL) shares fell 18.1% to $18.25 in pre-market trading after the company reported worse-than-expected second-quarter financial results.
    • Regencell Bioscience Holdings Limited (NASDAQ:RGC) fell 16.3% to $11.30 in pre-market trading after declining 10% on Wednesday.
    • Hoth Therapeutics, Inc. (NASDAQ:HOTH) fell 15.9% to $0.8998 in pre-market trading. Hoth Therapeutics shares gained around 11% on Wednesday after the company signed an agreement with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer’s disease.
    • Bone Biologics Corporation (NASDAQ:BBLG) shares dipped 13% to $1.67 in pre-market trading after jumping 54% on Wednesday.
    • Ford Motor Company (NYSE:F) shares fell 13% to $11.90 in pre-market trading following a second-quarter earnings miss.

    Now Read This:

    • Nvidia, McDonald’s And 2 Other Stocks Insiders Are Selling
    Get the next $BBLG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBLG
    $BLMZ
    $CERO
    $DAWN

    CompanyDatePrice TargetRatingAnalyst
    Day One Biopharmaceuticals Inc.
    $DAWN
    3/10/2026$21.50Buy → Neutral
    H.C. Wainwright
    Ford Motor Company
    $F
    3/4/2026$17.00Buy
    BofA Securities
    Day One Biopharmaceuticals Inc.
    $DAWN
    1/13/2026$34.00Buy
    TD Cowen
    Edwards Lifesciences Corporation
    $EW
    1/9/2026$97.00Hold → Buy
    TD Cowen
    Ford Motor Company
    $F
    1/8/2026$16.00Neutral → Overweight
    Piper Sandler
    Edwards Lifesciences Corporation
    $EW
    12/18/2025$100.00Neutral → Overweight
    Analyst
    Edwards Lifesciences Corporation
    $EW
    11/3/2025$96.00Mkt Perform → Outperform
    Raymond James
    Viking Therapeutics Inc.
    $VKTX
    10/29/2025$106.00Buy
    Canaccord Genuity
    More analyst ratings

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kingsley Stuart A bought $29,953 worth of shares (940 units at $31.86), increasing direct ownership by 20% to 5,582 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 9:54:36 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $1,009 worth of shares (31 units at $32.56), increasing direct ownership by 0.55% to 5,716 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 8:12:31 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chair and Chair Ford William Clay Jr received a gift of 2,750 units of Class B Stock, bought $1,934,450 worth of Class B Stock (140,000 units at $13.82) and acquired 668,326 shares, increasing direct ownership by 141% to 995,908 units (SEC Form 4)

    4 - FORD MOTOR CO (0000037996) (Issuer)

    2/23/26 4:30:27 PM ET
    $F
    Auto Manufacturing
    Industrials

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kingsley Stuart A bought $29,953 worth of shares (940 units at $31.86), increasing direct ownership by 20% to 5,582 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 9:54:36 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $1,009 worth of shares (31 units at $32.56), increasing direct ownership by 0.55% to 5,716 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 8:12:31 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Viking Therapeutics Inc.

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    3/10/26 6:20:39 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Day One Biopharmaceuticals downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Day One Biopharmaceuticals from Buy to Neutral and set a new price target of $21.50

    3/10/26 8:39:03 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on Ford Motor with a new price target

    BofA Securities resumed coverage of Ford Motor with a rating of Buy and set a new price target of $17.00

    3/4/26 8:37:24 AM ET
    $F
    Auto Manufacturing
    Industrials

    TD Cowen resumed coverage on Day One Biopharmaceuticals with a new price target

    TD Cowen resumed coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $34.00

    1/13/26 8:59:51 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    SEC Filings

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Signing Day Sports Inc.

    425 - Signing Day Sports, Inc. (0001898474) (Subject)

    3/11/26 8:06:53 AM ET
    $SGN
    EDP Services
    Technology

    Signing Day Sports Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Signing Day Sports, Inc. (0001898474) (Filer)

    3/11/26 8:00:31 AM ET
    $SGN
    EDP Services
    Technology

    IF Bancorp Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - IF Bancorp, Inc. (0001514743) (Filer)

    3/10/26 4:45:47 PM ET
    $IROQ
    Savings Institutions
    Finance

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

    Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (NASDAQ:INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patient

    3/11/26 9:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CERo Therapeutics Provides Shareholder Update

    Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead investor, underscore the Company's operational momentum SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich: To our stockholders and stakeholders: Following our recent Form 8-K filing confirming receipt of convertible deb

    3/11/26 8:15:00 AM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Leadership Updates

    Live Leadership Updates

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CERo Therapeutics Provides Shareholder Update

    Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead investor, underscore the Company's operational momentum SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich: To our stockholders and stakeholders: Following our recent Form 8-K filing confirming receipt of convertible deb

    3/11/26 8:15:00 AM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Financials

    Live finance-specific insights

    View All

    Stellus Capital Investment Corporation Schedules 2025 Fourth Quarter and Annual Financial Results Conference Call

    HOUSTON, Feb. 26, 2026 /PRNewswire/ -- Stellus Capital Investment Corporation (NYSE:SCM) will release its financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, March 11, 2026 after the close of the stock market. Stellus Capital Investment Corporation will host a conference call to discuss these results on Thursday, March 12, 2026 at 10:00 AM, Central Time. The conference call will be led by Robert T. Ladd, Chief Executive Officer, and W. Todd Huskinson, Chief Financial Officer, Chief Compliance Officer, Treasurer, and Secretary.Conference Call D

    2/26/26 7:05:00 PM ET
    $SCM
    Finance/Investors Services
    Finance

    Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

    Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Financial Guidance Announced on January 8, 2026Conference Call at 8:00 A.M. EST Today RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

    2/26/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $BLMZ
    $CERO
    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    12/13/24 7:18:17 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care